UK’s NICE approves routine use of Ibrance^®(palbociclib) to treat advanced breast cancer

Ibrance® (palbociclib) with Faslodex® (fulvestrant) is the latest drug combination to be approved by the UK’s NICE for routine treatment of advanced breast cancer. Palbociclib is the 16th breast cancer medicine to be approved by NICE since 2018. Taken as a once-a-day pill, Ibrance is a life-extending option for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer. The drug is a CDK4/6 inhibitor, that functions to inhibit proteins that are essential for cancer cell growth and division. From 2020, palbociclib, made by Pfizer (US), has been made accessible by the Cancer Drugs Fund. Since then, data has...